ArticleMedical oncology (Northwood, London, England)2025
Deciphering the anti-cancer and anti-inflammatory activity in natural bioactive compounds of Typhonium flagelliforme: in silico approaches with special target to NEK7.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cancer is a great challenge and act as a crucial cause of death globally. Typhonium flagelliforme (T. flagelliforme), a medicinal plant, has been used to treat diverse diseases, including cancer. Consequently, natural compounds from this plant are being investigated for the development of potent and selective anti-cancer agents. A promising target, NEK7 interacts with NLRP3 to assemble the NLRP3 inflammasome critical complex in innate immune responses, and pyroptotic cell death. Altered NEK7 expression is connected to the progression of several cancers, making it a key target for therapy. However, the lack of effective NEK7 inhibitors highlights the urgent need to develop novel therapeutic strategies. The work aimed to identify potential anti-cancer compounds from T. flagelliforme that can act as NEK7 inhibitors for the management of lung cancer. We employed a range of computational techniques such as molecular docking, molecular dynamics (MD) simulations, and binding free energy (MM/PBSA) calculations, to evaluate the plant's bioactive compounds. Molecular docking revealed that several compounds, specifically Beta-Sitosterol, Cycloartane-3.beta.,25-diol, and Ergost-7-en-3-ol, showed higher binding scores -9.5 kcal/mol, -9.2 kcal/mol, and -9.4 kcal/mol, respectively, than the known reference inhibitor, F9N, which has binding scores of -9.1 kcal/mol. Further analysis through molecular dynamics simulations confirmed that Beta-Sitosterol, Cycloartane-3.beta.,25-diol, and Ergost-7-en-3-ol exhibit a strong and stable binding potential with NEK7. Moreover, binding free energy calculations showed that Cycloartane-3.beta.,25-diol has the highest binding free energy of -203.460 kJ/mol than the positive control (F9N), which has the binding free energy of -170.420 kJ/mol, strongly suggesting its effectiveness in modulating NEK7 signaling. Overall, this research shows that the compounds Cycloartane-3.beta., 25-diol and Beta-Sitosterol have great potential to inhibit NEK7, surpassing the known F9N compound. The study emphasizes the therapeutic potential of active compounds from T. flagelliforme for developing new cancer treatments.
Indexed as
Identifiers
41003845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.